ArticleAntibiotics (Basel, Switzerland)2022
NDM-1 Introduction in Portugal through a ST11 KL105
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- First report of carbapenemase-producing bacteria from poultry farms in the United Arab Emirates: an emerging One Health threat.Frontiers in veterinary science · 2026Article
- A decade of epidemiology and incidence of carbapenemase-producing bacteria in a tertiary hospital in southern Europe.Infection prevention in practice · 2025Article
- Whole-Genome Sequencing of Extended-Spectrum β-Lactamase-ProducingPathogens (Basel, Switzerland) · 2025Article
- Genomic characteristics of ST6115 carbapenem-resistantFrontiers in microbiology · 2025Article
- Tackling Carbapenem Resistance and the Imperative for One Health Strategies-Insights from the Portuguese Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- Activity of Epsilon-poly-L-lysine against Multidrug-ResistantBiomedicines · 2024Article
- Development and validation of a quick, automated, and reproducible ATR FT-IR spectroscopy machine-learning model forJournal of clinical microbiology · 2024Article
- In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria-A Pilot Study in Bulgaria.Antibiotics (Basel, Switzerland) · 2024Article
- Phylogenomics of Globally Spread Clonal Groups 14 and 15 of Klebsiella pneumoniae.Microbiology spectrum · 2023Article
- Occurrence of Multidrug-Resistant Bacteria Resulting from the Selective Pressure of Antibiotics: A Comprehensive Analysis of ESBLVeterinary sciences · 2023Article
- Exploring the Antibiotic Resistance Profile of ClinicalAntibiotics (Basel, Switzerland) · 2022Article
- Report and Comparative Genomics of an NDM-5-ProducingMicroorganisms · 2022Article
- Dissemination of High-Risk ClonesMicroorganisms · 2022Article
- First Belgian Report of Ertapenem Resistance in an ST11Antibiotics (Basel, Switzerland) · 2022Article
- Evaluation of Fourier Transform Infrared Spectroscopy as a First-Line Typing Tool for the Identification of Extended-Spectrum β-Lactamase-ProducingFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The changing epidemiology of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.